RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Estren Behaves as a Weak Estrogen Rather than a Non-genomic Selective Activator in the Mouse Uterus
Hewitt, SC., Collins, J., Grissom, S., Hamilton, K., & Korach, KS. (2006). Estren Behaves as a Weak Estrogen Rather than a Non-genomic Selective Activator in the Mouse Uterus. Endocrinology.
A proposed membrane-mediated mechanism of rapid non genomic response to estrogen has been the intense focus of recent research. Estren, a synthetic steroid, is reported to act selectively through a rapid membrane-mediated pathway, rather than through the classical nuclear estrogen receptor (ER)-mediated pathway, to maintain bone density in ovaierectomized mice without uterotropic effects. To further evaluate the mechanism and physiological effects of estren we studied responses in adult ovariectomized mice. In a three-day uterine bioassay, we found that 300 microg estren significantly increased uterine weight; in comparison, a more maximal response was seen with 1 microg estradiol (E2). The estren response was partly ERalpha-independent, as ERalpha knockout (alphaERKO) uteri also exhibited a more moderate weight increase. Estren induced epithelial cell proliferation in WT but not in the alphaERKO, indicating ERalpha-dependence of the epithelial growth response. Examination of estren-regulated uterine genes by microarray indicated that early (2 h) changes in gene expression are similar to the early responses to E2. These gene responses are ERalpha dependent, as they are not seen in the alphaERKO. Later estren-induced changes in gene expression (24 h) are blunted in comparison to those seen 24 h following E2. In contrast to early genes, these later estren responses are independent of ERalpha, as the alphaERKO shows a similar response to estren at 24 h. We found that E2 or estren treatments lead to depletion of ERalpha in the uterine cytosol fraction and accumulation in the nuclear fraction within 30-60 min, consistent with an ability of estren to regulate genes through a nuclear ERalpha rather than a non-genomic mechanism. Interestingly, estren, but not E2, induces accumulation of androgen receptor (AR) in the nuclear fraction of both WT and alphaERKO samples, suggesting that AR might be involved in the later ERalpha-independent genomic responses to estren. In conclusion, our studies suggest that estren is weakly estrogenic in the mouse uterus and might induce nuclear ERalpha and AR mediated responses. Given its activity in our uterine model, use of estren as a bone selective clinical compound needs to be reconsidered